Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity

Aboli Bhingarkar, Yuyin Wang, Keito Hoshitsuki, Katherine M. Eichinger, Sanjay Rathod, Yin Zhu, He Lyu, Andrew T. McNutt, Larry W. Moreland, Lee McDermott, David Ryan Koes, Christian A. FernandezFrontiers in Pharmacology 2025 · DOI

Abstract

Duvelisib (DV) is a promising NFAT inhibitor that can protect against TNFα inhibitor (TNFi) immunogenicity without inhibiting calcineurin phosphatase activity. Our results suggest that the future development of DV analogs may be of interest as agents to attenuate unwanted immune responses.

Introduction

Biological drugs, particularly TNFα inhibitors like adalimumab (Humira), are the standard of care for autoimmune conditions such as Rheumatoid Arthritis (RA). However, their efficacy is frequently compromised by immunogenicity—the patient's immune system recognizes the biologic as foreign and produces anti-drug antibodies (ADAs). These antibodies neutralize the drug, leading to treatment failure. While methotrexate (MTX) is currently used to suppress this response, its high toxicity often leads to patient non-compliance. This study identifies Duvelisib (DV), an FDA-approved leukemia drug, as a novel, dual-action agent capable of mitigating this immunogenicity through a previously unknown mechanism.

A Novel Mechanism of Action

Traditionally known as a PI3K-δ/γ inhibitor, Duvelisib was discovered to directly target the NFAT (Nuclear Factor of Activated T-cells) transcription factor. Unlike traditional NFAT inhibitors like Cyclosporin A (CsA), which prevent NFAT from entering the nucleus by inhibiting calcineurin, DV allows NFAT to translocate but physically blocks it from binding to its DNA consensus sequence.

Molecular docking simulations identifying the binding pocket of Duvelisib within the NFATC2 structure.

Computational modeling using the NFATC2 crystal structure (PDBID: 1OWR) and molecular dynamics simulations identified transient pockets where small molecules could bind. Docking studies confirmed that DV fits into a specific pocket that interferes with DNA binding, a finding later validated by DARTS (Drug Affinity Responsive Target Stability) and CETSA (Cellular Thermal Shift Assay) experiments.

Key Results and Functional Validation

Functional assays demonstrated that DV inhibits NFAT activation with an IC50 of 5.975 μM. Crucially, this effect was shown to be independent of PI3K inhibition; other potent PI3K inhibitors did not replicate the same level of NFAT suppression.

Comparative analysis of NFATC1 inhibition showing Duvelisib's significant inhibitory effect relative to DMSO and CsA controls.

In vivo studies using mouse models of adalimumab immunogenicity revealed that a 45 mg/kg dose of DV was more effective than clinical equivalent doses of methotrexate at reducing anti-adalimumab IgG antibodies. Ex vivo analysis further confirmed that DV attenuates CD4+ T cell proliferation and B cell antibody secretion, the primary drivers of the ADA response.

Discussion and Future Directions

While Duvelisib is already FDA-approved, its current clinical use is limited by a "black box" warning related to PI3K-associated toxicities, such as neutropenia. However, this research establishes DV as a vital structural scaffold. By identifying the specific NFAT-binding mechanism, researchers can now focus on developing DV analogs that retain potent NFAT-blocking capabilities while eliminating PI3K-inhibiting activity. Such analogs could provide a safer, more targeted alternative to methotrexate for "cloaking" biologics from the immune system, potentially revolutionizing the long-term management of chronic autoimmune diseases.

Summary updated

Abstract

DV is a promising NFAT inhibitor that can protect against TNFi immunogenicity without inhibiting calcineurin phosphatase activity. Our results suggest that the future development of DV analogs may be of interest as agents to attenuate unwanted immune responses.
BibTeX
@inproceedings{bhingarkar2025duvelisib,
  author = {Aboli Bhingarkar and Yuyin Wang and Keito Hoshitsuki and Katherine M. Eichinger and Sanjay Rathod and Yin Zhu and He Lyu and Andrew T. McNutt and Larry W. Moreland and Lee McDermott and David Ryan Koes and Christian A. Fernandez},
  title = {{Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2024.1397995},
}
Figure